Primary immunodeficiency-related bronchiectasis in adults: comparison with bronchiectasis of other etiologies in a French reference center.
Adult
Age Factors
Bronchiectasis
/ diagnosis
Cause of Death
Cohort Studies
Comorbidity
Cystic Fibrosis
Female
France
/ epidemiology
Humans
Male
Middle Aged
Prevalence
Primary Immunodeficiency Diseases
/ diagnosis
Prognosis
Respiratory Function Tests
Retrospective Studies
Risk Assessment
Severity of Illness Index
Sex Factors
Survival Analysis
Tertiary Care Centers
Bronchiectasis
Common variable immune deficiency
Immunoglobulins
Primary immunodeficiency
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
04 Dec 2019
04 Dec 2019
Historique:
received:
30
07
2019
accepted:
14
11
2019
entrez:
6
12
2019
pubmed:
6
12
2019
medline:
6
5
2020
Statut:
epublish
Résumé
Bronchiectasis is a heterogeneous disease depending on etiology. It represents the most frequent non-infectious pulmonary complication of primary immunodeficiencies (PID). We investigated whether bronchiectasis associated with PID had a distinct course in comparison to bronchiectasis of other causes. Retrospective single-center study of adult patients diagnosed with non-cystic fibrosis bronchiectasis with more than 5 years of follow-up and at least 4 pulmonary functional tests available at one year apart. They were divided into three groups: PID- related bronchiectasis, idiopathic/post infectious-related bronchiectasis and other causes of bronchiectasis. Respiratory functional data and clinical outcomes were compared. Of 329 patients with bronchiectasis diagnosed in Foch Hospital (Suresnes, France), 98 patients fulfilled the selected criteria (20 PID-related cases, 39 idiopathic or post-infectious cases, and 39 cases with other causes). Median time of follow-up was 9.5 years. Groups were similar concerning initial characteristics (female 70.4%, never smokers 59.2%, mild severity bronchiectasis according to the FACED score and median FEV1 at diagnosis 73.5% predicted values [Q1-Q3: 53.75-90.5]), except PID patients who were younger (median age of 51.5 vs 62 years, p = 0.02). Eighty-five percent of PID patients received immunoglobulin substitution (median trough level was measured at 10.5 g/dl [10;10.92]). Global median FEV1 annual decline was 25.03 ml/year [8.16;43.9] and 19.82 ml/year [16.08;48.02] in the PID patients group. Forty-five percent of patients had bacterial colonization, pneumoniae occurred in 56% of patients and median exacerbation annual rate was 0.8 [0.3-1.4]. Hemoptysis occurred in 31.6% of patients. Global mortality rate was 11.2%. We did not record any significant difference for all clinical and functional outcomes between patients with PID and other etiologies. The median decline in FEV1 was similar in the three groups. The course of PID-related bronchiectasis was similar to bronchiectasis of other causes. Provided that patients receive immunoglobulin replacement, the course of PID-related bronchiectasis seems to be independent of the underlying immune disorder.
Sections du résumé
BACKGROUND
BACKGROUND
Bronchiectasis is a heterogeneous disease depending on etiology. It represents the most frequent non-infectious pulmonary complication of primary immunodeficiencies (PID). We investigated whether bronchiectasis associated with PID had a distinct course in comparison to bronchiectasis of other causes.
METHODS
METHODS
Retrospective single-center study of adult patients diagnosed with non-cystic fibrosis bronchiectasis with more than 5 years of follow-up and at least 4 pulmonary functional tests available at one year apart. They were divided into three groups: PID- related bronchiectasis, idiopathic/post infectious-related bronchiectasis and other causes of bronchiectasis. Respiratory functional data and clinical outcomes were compared.
RESULTS
RESULTS
Of 329 patients with bronchiectasis diagnosed in Foch Hospital (Suresnes, France), 98 patients fulfilled the selected criteria (20 PID-related cases, 39 idiopathic or post-infectious cases, and 39 cases with other causes). Median time of follow-up was 9.5 years. Groups were similar concerning initial characteristics (female 70.4%, never smokers 59.2%, mild severity bronchiectasis according to the FACED score and median FEV1 at diagnosis 73.5% predicted values [Q1-Q3: 53.75-90.5]), except PID patients who were younger (median age of 51.5 vs 62 years, p = 0.02). Eighty-five percent of PID patients received immunoglobulin substitution (median trough level was measured at 10.5 g/dl [10;10.92]). Global median FEV1 annual decline was 25.03 ml/year [8.16;43.9] and 19.82 ml/year [16.08;48.02] in the PID patients group. Forty-five percent of patients had bacterial colonization, pneumoniae occurred in 56% of patients and median exacerbation annual rate was 0.8 [0.3-1.4]. Hemoptysis occurred in 31.6% of patients. Global mortality rate was 11.2%. We did not record any significant difference for all clinical and functional outcomes between patients with PID and other etiologies. The median decline in FEV1 was similar in the three groups.
CONCLUSIONS
CONCLUSIONS
The course of PID-related bronchiectasis was similar to bronchiectasis of other causes. Provided that patients receive immunoglobulin replacement, the course of PID-related bronchiectasis seems to be independent of the underlying immune disorder.
Identifiants
pubmed: 31801528
doi: 10.1186/s12931-019-1242-4
pii: 10.1186/s12931-019-1242-4
pmc: PMC6894192
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
275Références
J Allergy Clin Immunol. 2006 Apr;117(4 Suppl):S525-53
pubmed: 16580469
Radiology. 1991 Jun;179(3):783-8
pubmed: 2027992
Clin Immunol. 2010 Oct;137(1):21-30
pubmed: 20675197
J Allergy Clin Immunol. 2014 Jul;134(1):116-26
pubmed: 24582312
Clin Exp Immunol. 2013 Feb;171(2):117-23
pubmed: 23286938
Antimicrob Agents Chemother. 2008 Jan;52(1):137-45
pubmed: 17954687
J Allergy Clin Immunol. 2010 Feb;125(2):424-432.e8
pubmed: 20159255
Eur Respir J. 2015 Jun;45(6):1613-23
pubmed: 25614174
Acta Paediatr Scand. 1966;:Suppl 165:1+
pubmed: 5908517
Respirology. 2014 Nov;19(8):1178-82
pubmed: 25183304
Ann Am Thorac Soc. 2015 Dec;12(12):1764-70
pubmed: 26431397
Chest. 2012 Jul;142(1):159-167
pubmed: 22267679
Int Immunopharmacol. 2004 Jun;4(6):745-53
pubmed: 15135316
Clin Immunol. 1999 Jul;92(1):34-48
pubmed: 10413651
Respiration. 2016;92(1):1-8
pubmed: 27336790
Thorax. 1974 May;29(3):304-12
pubmed: 4855384
J Allergy Clin Immunol. 2011 Jun;127(6):1414-7
pubmed: 21546068
J Allergy Clin Immunol Pract. 2018 Jan - Feb;6(1):159-168.e3
pubmed: 28734862
Thorax. 2019 Jan;74(Suppl 1):1-69
pubmed: 30545985
J Clin Immunol. 2014 Jan;34(1):68-75
pubmed: 24136152
Clin Infect Dis. 2008 May 15;46(10):1547-54
pubmed: 18419489
J Allergy Clin Immunol. 2012 Mar;129(3):770-7
pubmed: 22153772
J Allergy Clin Immunol. 2008 Jul;122(1):210-2
pubmed: 18602574
J Microbiol Immunol Infect. 2006 Apr;39(2):114-20
pubmed: 16604243
J Antimicrob Chemother. 2005 Jan;55(1):10-21
pubmed: 15590715
Scand J Clin Lab Invest. 2013 Sep;73(6):514-22
pubmed: 23957371
Ann Am Thorac Soc. 2015 May;12(5):701-7
pubmed: 25679336
Clin Infect Dis. 2014 Nov 15;59(10):1462-70
pubmed: 25124061
Respir Med. 2014 Feb;108(2):287-96
pubmed: 24445062
JAMA. 2013 Mar 27;309(12):1251-9
pubmed: 23532241
Respir Med. 2007 Jun;101(6):1163-70
pubmed: 17223027
Chest. 2007 Nov;132(5):1565-72
pubmed: 17998359
Clin Exp Allergy. 2012 Sep;42(9):1302-12
pubmed: 22925316
Thorax. 2017 Feb;72(2):161-166
pubmed: 27573451
Ann Am Thorac Soc. 2014 May;11(4):496-503
pubmed: 24592925
Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1277-84
pubmed: 11029331
Surg Gynecol Obstet. 1955 Jun;100(6):643-50
pubmed: 14373373
Eur Respir J. 2014 May;43(5):1357-67
pubmed: 24232697
Respir Med. 2013 Jul;107(7):1001-7
pubmed: 23672995
Respir Med. 2006 Dec;100(12):2183-9
pubmed: 16650970
Lancet. 2012 Aug 18;380(9842):660-7
pubmed: 22901887
J Allergy Clin Immunol. 2010 Jun;125(6):1354-1360.e4
pubmed: 20471071
Eur Respir J. 2009 Oct;34(4):843-9
pubmed: 19357155
Lancet Respir Med. 2018 Sep;6(9):715-726
pubmed: 29478908
Clin Exp Immunol. 2008 Sep;153(3):324-30
pubmed: 18637104